AMRA-MEDICAL
11.12.2018 12:30:06 CET | Business Wire | Press release
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the US. AMRA® Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements.
AMRA is the first in the world to transform MR-images from a 6-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status.
“We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure, ” stated Eric Converse, CEO of AMRA.
“AMRA® Profiler helps address these challenges by providing physicians with the most detailed body composition assessment and imaging available, cost-effectively and with minimal intrusion to the patient. Ultimately this enables clinicians to make more informed treatment decisions about the whole body. This clearance is the next step in our journey of translating the benefits of AMRA into clinical practice and in ultimately contributing to the real world data and real world evidence that are playing an increasing role in health care decisions today .”
AMRA® Profiler provides a number of body composition measurements, such as visceral adipose tissue volume, subcutaneous adipose tissue volume, liver fat fraction, and thigh muscle volume, alongside associated medical images. These body composition measurements and images, when interpreted by a trained physician, may yield information that assists in diagnosis.
AMRA’s mission is to establish a new global standard in body composition analysis and confront global health challenges by enhancing the evidence base needed to predict and prevent disease.
-ENDS-
Notes to editor:
About AMRA:
AMRA is a ground-breaking, international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, delivering multiple fat and muscle biomarkers with unrivalled precision alongside contextual disease insights – all from a 6-minute whole-body MRI scan. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making, from clinical research to clinical care.
AMRA® Profiler precisely measures fat volumes, fat fractions, and lean tissue volumes - precise body composition measurement available as a decision support tool for use in clinical practice. AMRA® Profiler is also CE marked in Europe and available for clinical use in Sweden, UK and Germany.
For more information, visit www.amramedical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005392/en/
Contact:
AMRA Chelsea Ranger SVP Commercial & Market Strategy chelsea.ranger@amramedical.com MSL Rebecca Snazelle Director, Health +44 (0)7773 034 198 rebecca.snazelle@mslgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press release
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The
Semiconductor Companies Get Tough on AI Investment, but Measuring Returns Remains a Challenge9.11.2026 12:03:00 CET | Press release
HTEC research finds semiconductor companies are ahead in scaling AI, yet fragmented measurement is making it harder to connect engineering gains to business outcomes HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109039341/en/ HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. Nearly half (48%) of semiconductor respondents describe their organizations as scaling AI or already AI-native, comp
GoFundMe Surpasses $50 Billion Raised, Celebrating the People Powering a Global Movement of Help9.11.2026 12:00:00 CET | Press release
The inaugural Kind 50 list celebrates the people behind the milestone – and how help brings people closer together GoFundMe today announced that its global community has surpassed $50 billion raised to help individuals and nonprofits around the world. More than 200 million people have donated through GoFundMe, and nearly 40% have given more than once, reflecting the extraordinary scale of people showing up for one another – and continuing to come back to help. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109255455/en/ Celebrating $50B raised on GoFundMe with The Kind 50. From showing up for a friend in need to mobilizing entire communities, The Kind 50 celebrates people and organizations whose acts of kindness – on and off GoFundMe – made an impact over the past year and inspired others to help. To mark the milestone, GoFundMe is introducing The Kind 50, a celebration of the internet’s kindest people. The inaugural list
Prodalim Reports Q3 2026 Results, with Growth in its Specialty Ingredients & Solutions Business and Solos Activity Net Profit and Cashflow from Operating Activities9.11.2026 11:18:00 CET | Press release
Group revenues for the quarter grew 7% reaching US$98.4 million.SIS revenues (Specialty Ingredients & Solutions) grew 30% in Q3 reaching US$20 million.Adjusted EBITDA1 for the SIS grew 37% reaching US$4.3 million, reflecting an adjusted EBITDA margin of 21.4%.Juice Solutions revenues grew 2% in the quarter to US$78 million, improvement in adjusted EBITDA margin to 11.0%.Group’s adjusted net profit grew 34% reaching US$4.2 million.Cashflow from operating activities in the quarter was strong, increasing to US$16.7 million.Last week, the Company announced a strategic acquisition, of BOK, a South African company that produces natural ingredients, high value grape based specialty using circular economy principles. Regulatory News: Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth across all key operating parameters, alongside an important strategic acquisition. We continue to make substantial investments in production i
Logistics Reply named a Leader in the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing9.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail 2026 Vendor Assessment (doc #US53701926, October 2026) as well as in the IDC MarketScape: Worldwide Warehouse Management for Manufacturing 2026 Vendor Assessment (doc #US53013526, October 2026). The reports evaluate vendors based on strategy and product capabilities, looking at both quantitative and qualitative criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109197861/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing. LEA ReplyTM is Logistics Reply’s cloud-native warehouse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom